Bacterial Infections
RSSArticles
-
Updated Recommendations for Drug-Susceptible and Drug-Resistant Tuberculosis
The authors provide an update of recommendations for the treatment of tuberculosis, including cases with drug resistance. The recommendations include the use of newer drugs that have undergone clinical trials and shorter durations of therapy.
-
Why Does Colonization Become Active C. difficile?
These authors performed a nested case-control study to identify risk factors for the progression from Clostridioides difficile colonization to active infection in hospitalized persons.
-
Staphylococcus aureus Endocarditis: A Selection of Just-Published Studies
A selection of reports published in the last two months cover microbiologic diagnosis and management issues.
-
Antibiotics for Asymptomatic Bacteriuria: Using Urinalysis to Improve Stewardship
A cohort study found that in patients receiving antibiotics for a urinary tract infection, a urinalysis with pyuria and/or nitrituria identified 40% more cases of unnecessary antibiotic use compared to asymptomatic bacteriuria.
-
Gepotidacin Tablets (Blujepa)
The U.S. Food and Drug Administration has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections.
-
Antibiotics for Asymptomatic Bacteriuria: Using Urinalysis to Improve Stewardship
A cohort study found that in patients receiving antibiotics for a urinary tract infection, a urinalysis with pyuria and/or nitrituria identified 40% more cases of unnecessary antibiotic use compared to asymptomatic bacteriuria.
-
Bacterial Vaginosis: Treat the Man, Too
In a randomized trial, treatment of the regular male partner with oral and topical agents was strongly associated with a reduced risk of recurrence of bacterial vaginosis in the female partner.
-
Noninferiority of Seven vs. 14 Days of Antibiotic Therapy for Bloodstream Infections
In this multinational, noninferiority trial that included more than 3,600 hospitalized patients with bloodstream infections from various pathogens and infectious syndromes, seven days of antibiotic therapy was noninferior to 14 days with respect to death from any cause by 90 days. Patients were excluded if they had severe immunosuppression or foci requiring prolonged treatment, or if their blood cultures yielded Staphylococcus aureus or possible contaminants. Various secondary outcomes were similar between the two groups.
-
Sulopenem Etzadroxil and Probenecid (Orlynvah)
The U.S. Food and Drug Administration has approved a combination of sulopenem and probenecid for the treatment of uncomplicated urinary tract infections.
-
Preventing Recurrent UTI with Probiotics
About half of women experience urinary tract infection (UTI) during their lifetime, and around 20% to 25% will experience recurrent UTI (defined as three or more UTIs in a 12-month period or two UTIs in a six-month period). Those with two UTIs in a six-month period have a 50% chance of a third UTI. Repeated courses of antibacterials distort both intestinal and vaginal flora, further increasing the risk of urinary infection.